EMA

London, United Kingdom
London, United Kingdom

Time filter

Source Type

News Article | April 25, 2017
Site: www.businesswire.com

ALBUQUERQUE, N.M.--(BUSINESS WIRE)--Optomec, a leading global supplier of production grade additive manufacturing systems for 3D printed electronics, announced today that the company, along with its partner Wong’s Kong King Ltd (WKK), will showcase its Aerosol Jet systems for 3D printed electronics at NEPCON China in Shanghai. The conference/expo will be held April 25-27 at the Shanghai World Expo and Convention center in China. Optomec will be located in the WKK booth # 1-F50 in Hall 1. At the expo, Optomec will display next generation 3D printed electronic devices used in consumer electronics, semiconductor packaging and Internet of Things applications. Also in the WKK booth, Optomec will showcase a video highlighting the use of Aerosol Jet technology in mass production at the LITE-ON Mobile Mechanical SBG (LITE-ON) factory in Guangzhou, China. For over one year, multiple Aerosol Jet production systems have been operating 24x7 at LITE-ON printing conformal electronics onto millions of consumer electronic devices. Since the printing process requires no plating or special resins, logistics are simplified and production costs are lowered. Examples of Aerosol Jet printed sensors and antennas will also be available for inspection. Additionally, on April 26, Dr. James Q. Feng, Principal Engineer at Optomec, will deliver a presentation titled “Aerosol Jet-The Enabling Technology for 3D Printed Electronics.” Dr. Feng will explain how Aerosol Jet technology is used by a wide variety of industries to directly print functional electronic circuitry and components onto low-temperature, non-planar substrates, without the need for masks, screens or plating. Optomec solutions for printed electronics are based on its industry proven Aerosol Jet technology for printing conformal electronic circuitry and components onto 3D structures. The Aerosol Jet process utilizes an innovative aerodynamic focusing technique to collimate a dense mist of material-laden micro droplets into a tightly controlled beam to print features as small as 10 microns or as large as several millimeters in a single pass. A wide assortment of materials can be printed with the Aerosol Jet system, including conductive nano-particle inks, polymers and epoxies, along with dielectrics, ceramics and bio-active materials. For more information on Optomec solutions for 3D printed electronics click here. NEPCON China is a prestigious professional trade platform and exhibition focused on SMT (surface mount technology) and EMA (electronics manufacturing automation). It brings together over 450 renowned brands from the electronics manufacturing industry around the globe with innovative equipment, materials and system integration solutions covering such areas as SMT, electronics manufacturing automation, welding, dispensing, spray coating, testing and measurement. Various technical forums at the venue allow the audience to meet with industry leaders and gain insight into industry trends and technology applications. For more information on the conference, click here. Optomec is a privately held, rapidly growing supplier of Additive Manufacturing systems. Optomec’s patented Aerosol Jet Systems for printed electronics and LENS 3D Printers for metal components are used by industry to reduce product cost and improve performance. Together, these unique printing solutions work with the broadest spectrum of functional materials, ranging from electronic inks to structural metals and even biological matter. Optomec has more than 300 marquee customers around the world, targeting production applications in the Electronics, Energy, Life Sciences and Aerospace industries. LENS (Laser Engineered Net Shaping) is a registered trademark of Sandia National Laboratories. Aerosol Jet and Optomec are registered trademarks of Optomec Inc.


News Article | April 17, 2017
Site: www.prweb.com

d-Wise Technologies, a leading global technology consultancy and clinical software provider, today announced the availability of a new cloud platform with managed services specifically developed for the biopharmaceutical and contract research industries. The Clinical Acceleration Platform, d-Wise’s latest clinical “as-a-service” cloud solution, is designed to provide rapid deployment of SAS and other software tools, accelerating time to insight and decision-making from a pre-validated, compliant and secure hosted environment. The Clinical Acceleration Platform is the result of close collaboration between SAS and d-Wise and is designed to completely eliminate the regulatory burden associated with clinical systems validation, and accelerate the clinical development lifecycle through improved collaboration, efficient data acquisition, secure data storage, and fast aggregation and analysis. d-Wise, a SAS Gold Partner, is recognized as a leading performer in delivering technology such as SAS Grid Computing and other software products embedded with SAS, including Reveal©, a clinical search tool, and Blur©, the industry-leading clinical trial data de-identification software solution. “The ability to instantly deploy a cloud-based SAS validated environment – and be the first to do this – is very exciting for d-Wise and our clients,” said Tom Dieker, Vice President of Global Client Engagement at d-Wise. “As a trusted SAS Partner, we see this new, instantly available, validated solution as being able to directly address the multitude of challenges faced by biotech, pharma and CROs – particularly the ability to focus on science and not IT deployment, with an ultimate goal of accelerating the drug development cycle.” Data insights are the key to many of the biggest challenges currently facing life sciences organizations. By making SAS’ sophisticated data analytics capabilities available on demand, via a “pay-by-month” or “pay-by-study” cloud delivery model, d-Wise is offering the most streamlined way yet for life sciences organizations – including biotech, pharma and clinical research organisations (CROs) – to turn operational data into actionable intelligence. “We’ve discovered that many SAS customers want quicker solutions but don’t always have the necessary expertise, staffing or budgets to execute,” said Rob Spee, Director of Global Channel Programs at SAS. “d-Wise is a valued Gold Partner who has bundled a much-needed solution that customers require into a turnkey, cloud-based offering that limits the need for additional personnel and lowers risks associated with deploying a new infrastructure. No installation or integration is required, which means they can quickly implement analytic solutions on demand. This results in lower overall IT costs and faster, more substantial ROI.” The instant availability of the Clinical Acceleration Platform will level the playing field, allowing smaller life sciences companies to respond to a range of new industry demands, without having to buy expensive software licences and maintain these internally. d-Wise’s Clinical Acceleration Platform is built on SAS Foundation 9.4 analytics software and includes a suite of best-of-breed clinical software tools and managed services. The platform is highly flexible and scalable, making it potentially available to the widest range of people in any location. The platform is hosted in secure global data centers that meet the highest criteria for resilience, data safeguarding and regulatory compliance. Because it is a validated and compliant environment, organizations will be freed from time-consuming validation processes required by regulatory agencies like the EMA and FDA. d-Wise will introduce the Clinical Acceleration Platform during an upcoming webinar, “How to deploy a secure, compliant, cloud -based SAS clinical computing platform…in 24 hours.” on April 20th at 11:00AM EST. http://www.bio-itworld.com/d-wise-how-to-deploy-a-secure-compliant-cloud/. To learn more about d-Wise please visit http://www.d-wise.com About d-Wise d-Wise Technologies, Inc. http://www.d-wise.com is a technology leader with the expertise to empower world-class life science and healthcare organizations to resolve their business optimization challenges, and help them rapidly harness change by leveraging data, systems and processes to gain competitive advantage. The d-Wise Life Sciences Practice has been providing clinical advisory and modernization services to our clients for over fourteen years. d-Wise consultants engage with life science clients to adopt a progressive and comprehensive approach to modernizing clinical trials through well-designed solutions and processes. d-Wise looks at your systems, processes, architecture, etc. – and identifies those elements that inhibit your ability to achieve your clinical research goals. We then empower you to reach those goals by modernizing your software and solutions, business processes, and infrastructure. We tailor all solutions to meet our individual client needs and deliver the most efficient data integration, data warehousing and standards solutions within highly regulated industries exhibiting domain expertise that’s rooted in knowledge of SAS software, clinical drug development and clinical data standards like CDISC. Our end-to-end expertise and assessment services encompass business process and change management; data and metadata-driven strategies; and vendor-agnostic infrastructure and technology assessments. In healthcare, d-Wise helps organizations develop an analytic vision, and integrate and streamline data operations for rapid deployment of visual intelligence solutions and advanced analytic models. d-Wise is well-known for their expertise and capability to implement advanced analytic solutions and improve operations, lower costs, improve health outcomes quality and facilitate executive decision-making. We have a broad range of experience that includes data optimization for actuarial, quality, medical-management, and operational functions, as well as support for IT and data organizations looking to implement best practices.


News Article | April 21, 2017
Site: www.accesswire.com

LONDON, UK / ACCESSWIRE / April 21, 2017 / Active Wall St. blog coverage looks at the headline from AbbVie Inc. (NYSE: ABBV) as the Company announced on April 20, 2017, that its Phase 3 EXPEDITION-1 study demonstrated that 99% of chronic hepatitis C virus (HCV) infected patients achieved sustained virologic response at 12 weeks' post-treatment (SVR12) with its investigational, pan-genotypic regimen of glecaprevir/pibrentasvir (G/P). Register with us now for your free membership and blog access at: http://www.activewallst.com/register/. One of AbbVie's competitors within the Drug Manufacturers - Major space, Impax Laboratories, Inc. (NASDAQ: IPXL), announced on April 06, 2017, that it will release its Q1 2017 financial results on Wednesday, May 10, 2017, prior to the open of the US financial markets. The Company will host a conference call and live webcast with the investment community at 8:30 a.m., ET on May 10, 2017. AWS will be initiating a research report on Impax Labs in the coming days. Today, AWS is promoting its blog coverage on ABBV; touching on IPXL. Get all of our free blog coverage and more by clicking on the link below: http://www.activewallst.com/register/. AbbVie's EXPEDITION-1 is a single arm, multicenter, open-label study evaluating the efficacy and safety of 12 weeks of G/P in adults with GT1, 2, 4, 5 or 6 chronic HCV infection and compensated cirrhosis (Child-Pugh A) in 146 patients, including those new to treatment or had prior treatment experience with IFN-based treatments. The primary endpoint was the percentage of patients achieving SVR12. SVR12 was achieved by 145/146 patients, with one GT1a-infected patient experiencing relapse. These high SVR12 rates were seen following 12 weeks of G/P treatment without ribavirin. Patients with specific virus strains associated with resistance or with a high quantity of the virus in their bloodstream before treatment initiation were not excluded from the study. "We have already seen great progress in the treatment of HCV patients with compensated cirrhosis. However, treatment challenges remain related to the use of ribavirin," said Xavier Forns, M.D., head of hepatitis unit, Hospital Clinic de Barcelona, Spain, "The positive findings from the EXPEDITION-1 study, along with previously reported data, show that G/P has the potential to become a ribavirin-free treatment for patients with compensated cirrhosis across these genotypes." In the EXPEDITION-1 study, the majority of adverse events (AEs) were mild and no patients discontinued treatment due to an AE. The most common AEs were fatigue and headache. No patients experienced ALT elevations equal to or above Grade 3. Of the 11 patients who experienced serious AEs, none were considered treatment-related. Approximately 130 to 150 million people worldwide are living with chronic HCV, for whom the risk of cirrhosis of the liver is between 15-30% within 20 years. Treatment guidelines around the world recommend that all patients with cirrhosis should be considered for treatment, yet the treatment of specific patients with HCV and compensated cirrhosis is still challenging. AbbVie's glecaprevir/pibrentasvir (G/P) is an investigational, pan-genotypic regimen being evaluated as a potential cure in 8 weeks for HCV patients without cirrhosis and who are new to treatment with direct-acting antivirals (DAA), which make up the majority of HCV patients. AbbVie's G/P is a once-daily regimen that combines two distinct antiviral agents. G/P is a fixed-dose combination of glecaprevir (300mg), an NS3/4A protease inhibitor, and pibrentasvir (120mg), an NS5A inhibitor, dosed once-daily as three oral tablets. AbbVie is also studying G/P in patients with specific treatment challenges, such as genotype 3, patients who were not cured with previous DAA treatment and those with CKD, including patients on dialysis. Authorization applications for G/P are currently under review by regulatory authorities around the world. G/P has been granted accelerated assessment by the European Medicines Agency (EMA), and priority review designations by the US Food and Drug Administration (FDA), and Japanese Ministry of Health, Labor and Welfare (MHLW). On Thursday, April 20, 2017, the stock closed the trading session at $63.78, slightly up 0.52% from its previous closing price of $63.45. A total volume of 5.70 million shares have exchanged hands. AbbVie's stock price advanced 4.94% in the last three months, 5.71% in the past six months, and 9.53% in the previous twelve months. Furthermore, since the start of the year, shares of the Company have gained 3.90%. The stock is trading at a PE ratio of 17.47 and has a dividend yield of 4.01%. Active Wall Street (AWS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. AWS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. AWS has not been compensated; directly or indirectly; for producing or publishing this document. The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by AWS. AWS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way. AWS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. AWS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, AWS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither AWS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.activewallst.com/disclaimer/. For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.


News Article | April 18, 2017
Site: www.prnewswire.com

«Nos dimos cuenta al principio que apoyar un identificador común y robusto a través de nuestras cadenas de suministro, en armonía con la norma específica del sector EMA Avails, nos permitiría realizar un gran ahorro debido a su eficiencia. Además, una mejora de la automatización mejoraría el plazo de lanzamiento de los activos de entretenimiento de nuestros proveedores de contenidos asociados», afirmó Bill Kotzman, Director de Asociados/Productos de YouTube/Google, y miembro del consejo de EIDR. «Y ahora, EIDR es una parte integrante de la automatización de los informes financieros para nosotros y para nuestros proveedores de contenidos asociados». Este anuncio es un hito importante en el esfuerzo concertado entre Google Play y los proveedores de contenidos, incluyendo a los grandes estudios de Hollywood, también ellos miembros titulares de EIDR. «El viaje de ida y vuelta» de EIDR proporciona las muy esperadas eficiencias en la cadena de suministro digital, que da como resultado unas revolucionarias mejoras sistémicas en la redacción de informes financieros y capacidades de facturación para todo el sector»," dice Kelly Fong-Bouchey, Director, Relaciones con el Cliente y Operaciones, Warner Bros. Technology. «El equipo de Warner Bros. Technology está entusiasmado porque Google, un socio de distribución digital clave, ha adoptado e integrado el «viaje de ida y vuelta» de EIDR en su flujo de trabajo." «Sony Pictures Entertainment ha adoptado el EIDR en la totalidad de sus sistemas de datos y, más recientemente, como la clave de la automatización de la cadena de suministro digital transaccional», afirmó Ellen Goodridge, SVP Cadena de Suministro Digital y Desarrollo de Productos, Sony Pictures Home Entertainment. «La finalización del «viaje de ida y vuelta» de EIDR con Google Play representa una oportunidad para ampliar la automatización basada en estándares que incrementará la eficiencia en el negocio digital premium». «Disney está muy satisfecho de ver el progreso que EIDR ha realizado en su capacidad de impulsar eficiencias a través de flujos de trabajo automatizados basados en estándares a lo largo y ancho de su cadena de suministro digital integrada», dice Christopher Stefanidis, Vicepresidente, Operaciones y Estrategia de Distribución Digital, Walt Disney Pictures and Television. «Lograr este hito inicial sobre el «viaje de ida y vuelta» supone un paso importante y esperamos establecer muchos otros usos específicos para EIDR y nuestros asociados del sector». Acerca de EIDR: EIDR (Registro Identificador de Entretenimiento) es un sistema de identificación universal para activos filmográficos y televisivos. Desde títulos de alto nivel, ediciones y DVD a codificaciones, clips y «mash-ups», EIDR proporciona identificadores altamente depurados, únicos a nivel mundial, para la totalidad de la gama de tipos de objeto audiovisual relevantes para el comercio del entretenimiento. Para más información sobre EIDR, visite eidr.org.


News Article | June 6, 2017
Site: www.prweb.com

Enterprise Management Associates (EMA), a leading IT and data management research and consulting firm, today announced it will host a research webinar titled “Next-Generation IT Service Management—Changing the Future of IT: How Real Is It Today, and Where is It Going in the Future?,” featuring Dennis Drogseth, VP of research covering IT megatrends, snalytics and CMDB dystems at EMA. In ongoing research and interviews, EMA has witnessed the growing role of IT service management in many IT organizations. This growth is a result of progressive ITSM teams—with integrated capabilities to support asset management, operations, development and the IT executive and business community—becoming a hub in optimizing IT for both value and cost. During this webinar, Drogseth will provide insight into this new research, with some dramatic, and telling revelations. Some of the questions addressed will be: The webinar is Thursday, June 15 at 2:00 p.m. Eastern. Those who wish to attend can register at: http://research.enterprisemanagement.com/next-gen-itsm-2017-webinar-pr.html About EMA Founded in 1996, EMA is a leading industry analyst firm that specializes in providing deep insight across the full spectrum of IT and data management technologies. EMA analysts leverage a unique combination of practical experience, insight into industry best practices, and in-depth knowledge of current and planned vendor solutions to help clients achieve their goals. Learn more about EMA research, analysis, and consulting services for enterprise line of business users, IT professionals and IT vendors at http://www.enterprisemanagement.com or blogs.enterprisemanagement.com.


News Article | June 14, 2017
Site: www.prweb.com

Enterprise Management Associates (EMA™), a leading IT and data management research and consulting firm, has released a new research report titled “Next-Generation IT Service Management: Changing the Future of IT,” based on criteria defined by Dennis Drogseth, vice president of research at EMA. While IT service management (ITSM) has too often been viewed by the industry as an area of reactive management with fading process efficiencies and legacy concerns, this new study reveals that, in many organizations, ITSM is becoming a hub of innovation. ITSM is shown to unify IT across its many silos, promote and measure IT operational efficiencies, and consolidate insights critical for IT-to-business planning. This evolution, however, is not without its obstacles and challenges, nor is it taking place in all IT organizations. In this report, ITSM is examined from various perspectives, including organizational role of respondents, company size and vertical, geographical differences, and success-related patterns of behavior. Targeted at IT executives and technical adopters across not only ITSM teams but also operations, development and IT asset management (ITAM) teams, this report shows what is really occurring with ITSM initiatives in both North America and Europe and provides a blueprint for how best to accelerate forward into a next-generation status. “The catalytic role of ITSM teams both across IT, and in support of enterprise efficiencies, is still largely misunderstood by many in the industry,” said Drogseth. “This research spotlights ITSM team centricity in everything from IT asset management and enterprise process automation, to increasing support for agile and DevOps initiatives, integrated IT operations, and being a center for IT governance overall—just to name a few examples. This extended outreach means reassessing ITSM in terms of relevant stakeholders, processes, best practices and needed technologies, all of which is examined in our report.” A few of the key data points from this survey are: A detailed analysis of the research findings are available in the report, "Next-Generation IT Service Management: Changing the Future of IT." Key highlights from the research are available in the “Next-Generation IT Service Management: Changing the Future of IT” webinar. About EMA Founded in 1996, EMA is a leading industry analyst firm that provides deep insight across the full spectrum of IT and data management technologies. EMA analysts leverage a unique combination of practical experience, insight into industry best practices, and in-depth knowledge of current and planned vendor solutions to help its clients achieve their goals. Learn more about EMA research, analysis, and consulting services for enterprise line of business users, IT professionals, and IT vendors at http://www.enterprisemanagement.com or blogs.enterprisemanagement.com.


NEW YORK--(BUSINESS WIRE)--EasyVista Inc., a leading provider of service management for IT organizations, announced that key findings from EMA’s Next Generation IT Service Management: Changing the Future of IT report (co-sponsored by EasyVista) mirrors EasyVista’s own belief that the service desk is assuming an increasingly strategic role in the enterprise. It also supports EasyVista’s thesis that excellent user experience and simple, intuitive self-service are essential to achieving wide adoption among users. EMA, a leading IT and data management research and consulting firm, surveyed 264 companies across North America and Europe on a range of subjects related to ITSM. They found that the industry is breaking away from its reputation as outdated, reactive and inefficient to become a focal point for innovation. “In many organizations, ITSM is becoming a hub of innovation unifying IT across its many silos. ITSM promotes and measures IT efficiencies, consolidating insights critical for IT-to-business planning—a must for digital transformation and IT more broadly,” said Dennis Drogseth, Vice President of EMA and author of the research. “We’re excited to see EMA’s validation of what we are also seeing in the market,” said Jamal Labed, COO of EasyVista. “There is a palpable shift in the way companies view the role of ITSM. The service desk has expanded well beyond traditional IT support to become a destination for all kinds of services, many of which are based entirely on self-service. EasyVista customers are perfectly positioned to transform their service desk into a center of innovation.” Many of EMA’s research findings pointed to end user experience being a top priority. In particular: “The number of responses to varied questions that all pointed to user experience as the Holy Grail was striking,” said Drogseth. “While improving end user experience received the most responses as the strategic priority, the combined choice of mobility, self-service and intelligent bots—all core to user experience—appeared equally high on priorities. Furthermore, social IT, another core function enabling user experience, was listed as the most important functional capability by respondents.” “User experience is not simply about making things easy, it’s about creating an end-to-end experience that resembles what users have grown accustomed to in their lives outside of work—an experience that is second nature and requires no training,” said Labed. “This isn’t, however, going to be solved with just one technology. Instead, a mixture of support for mobility, social collaboration, intelligent bots and self-service is required to deliver the seamless user experience expected by today’s business users.” To download EMA’s report, please click here. EasyVista simplifies IT Service Management by making it easy to deliver and easy to use for today’s enterprise. EasyVista’s service management platform was created to help companies automate and personalize service delivery to improve IT efficiency and increase staff productivity. Today, EasyVista helps 1,000+ enterprises around the world radically improve service user experience, dramatically simplify and accelerate service creation, and reduce the total cost of IT service delivery. EasyVista serves companies across a variety of industries, including financial services, healthcare, higher education, technology, public sector, retail, manufacturing and more. Headquartered in New York and Paris, EasyVista is a rapidly growing global company backed by leading venture capitalists, and traded as ALEZV:EN. Founded in 1996, EMA is a leading industry analyst firm that specializes in providing deep insight across the full spectrum of IT and data management technologies. EMA analysts leverage a unique combination of practical experience, insight into industry best practices, and in-depth knowledge of current and planned vendor solutions to help clients achieve their goals. Learn more about EMA research, analysis, and consulting services for enterprise line of business users, IT professionals and IT vendors at http://www.enterprisemanagement.com or blogs.enterprisemanagement.com. You can also follow EMA on LinkedIn, Twitter and Facebook.


News Article | July 11, 2017
Site: www.prweb.com

Enterprise Management Associates (EMA), a leading IT and data management research and consulting firm, today announced it will host a webinar titled “Empower Your Organization with Data: Today’s Forward-Looking Company Strategically Uses Data,” featuring John L Myers, managing research director at EMA, Erin Haselkorn, head of market research at Experian Data Quality and Basil Brown, pre-sales engineer at Experian Data Quality. Data-driven organizations are winning in the market today. These organizations use data to derive information that dramatically alters business models and even creates completely new ones. The use of data puts these organizations in a position to gain advantage and expand it against laggard competitors. As a result, the chief data officer (CDO) is becoming a more prominent role. The CDO is brought on board to capitalize on big data opportunities and help create a competitive advantage through data. The CDO leads the organization to move quickly and strategically to implement and empower business stakeholders to make the most effective use of the information they collect. During this webinar, Myers, Haselkorn and Brown will discuss how organizations are taking the data-driven leap and how they can set themselves, and their CDO, up for success. The webinar is Wednesday, July 19 at 2:00 p.m. Eastern. Those who wish to attend can register at: http://research.enterprisemanagement.com/empower-your-org-with-data-webinar-pr.html About EMA Founded in 1996, EMA is a leading industry analyst firm that specializes in providing deep insight across the full spectrum of IT and data management technologies. EMA analysts leverage a unique combination of practical experience, insight into industry best practices, and in-depth knowledge of current and planned vendor solutions to help clients achieve their goals. Learn more about EMA research, analysis, and consulting services for enterprise line of business users, IT professionals and IT vendors at http://www.enterprisemanagement.com or blogs.enterprisemanagement.com.


News Article | July 20, 2017
Site: www.prweb.com

Enterprise Management Associates (EMA), a leading IT and data management research and consulting firm, today announced it will host a webinar titled “Learn Best Practices of a True Hybrid IT Management Approach” featuring Julie Craig, research director of application management at EMA, Rob Lamb, vice president of hybrid cloud at IBM, and Ben Fawcett, chief technology officer at Orb Data. Increasingly, high-performing IT operations organizations are seeking a more automated and integrated approach to managing IT infrastructures, cloud networks and applications operating in hybrid environments. Yet, the majority of incumbent IT management solutions provide visibility to discrete portions of the hybrid environment—essentially technology silos—versus delivering a truly integrated, automated and analytics-driven hybrid IT management solution. During this webinar, Craig, Lamb and Fawcett will discuss the challenges of managing today’s complex IT environments and the benefits associated with moving to a true hybrid IT management approach. They will also reveal how embarking on a strategy around hybrid IT management can help organizations: The webinar is Tuesday, August 1 at 1:00 p.m. Eastern. Those who wish to attend can register at: http://research.enterprisemanagement.com/best-practices-of-a-true-hybrid-IT-management-approach-webinar-pr.html Founded in 1996, Enterprise Management Associates (EMA) is a leading industry analyst firm that specializes in providing deep insight across the full spectrum of IT and data management technologies. EMA analysts leverage a unique combination of practical experience, insight into industry best practices, and in-depth knowledge of current and planned vendor solutions to help their clients achieve their goals. Learn more about EMA research, analysis, and consulting services for enterprise line of business users, IT professionals and IT vendors at http://www.enterprisemanagement.com or blogs.enterprisemanagement.com.


News Article | August 1, 2017
Site: www.prweb.com

Enterprise Management Associates (EMA), a leading IT and data management research and consulting firm, today announced it will host a webinar titled “From Bare Metal to Public Cloud and Containers - 5 Best Practices for Monitoring Modern Infrastructures,” featuring Torsten Volk, managing research director of hybrid cloud, software defined infrastructure and machine learning at EMA, and Umair Khan, product marketing manager at CA Technologies. DevOps, containers, public cloud and hyperconverged composable infrastructure are popular examples of new IT paradigms and technologies today, and there is no reason to believe that the pace of technology change will slow down in the future. While all of these technologies fuel innovation, they also increase complexity and often lead to the adoption of siloed and proprietary management and monitoring tools. EMA research shows that organizations suffer from this lack of unified monitoring solutions, which makes proactive maintenance more difficult and root cause analysis take longer as even advanced analytics solutions rely on a unified stream of comprehensive operations data to work effectively. To help organizations stay ahead of the curve, Volk and Khan will reveal the five most important best practices to monitor a hybrid infrastructure, as well as: Those who attend will receive a free copy of this new report. The webinar is Thursday, August 10 at 1:00 p.m. Eastern. Those who wish to attend can register at: http://research.enterprisemanagement.com/5-best-practices-for-monitoring-modern-infrastructures-webinar-pr.html About EMA Founded in 1996, EMA is a leading industry analyst firm that specializes in providing deep insight across the full spectrum of IT and data management technologies. EMA analysts leverage a unique combination of practical experience, insight into industry best practices, and in-depth knowledge of current and planned vendor solutions to help clients achieve their goals. Learn more about EMA research, analysis, and consulting services for enterprise line of business users, IT professionals and IT vendors at http://www.enterprisemanagement.com or blogs.enterprisemanagement.com.

Loading EMA collaborators
Loading EMA collaborators